Zalunfiban (Disaggpro™)
Pre-hospital treatment of ST-segment elevation myocardial infarction (STEMI)
Key Facts
About CeleCor Therapeutics
CeleCor Therapeutics is advancing zalunfiban, a subcutaneous GPIIb/IIIa inhibitor, to treat STEMI heart attacks at the first point of medical contact. The drug is engineered for rapid onset (maximal effect within 15 minutes) and a predictable, short duration of action, making it suitable for use by paramedics and in emergency departments. The company has completed enrollment in its pivotal Phase 3 CeleBrate trial, positioning it for a potential near-term regulatory filing if results are positive. CeleCor is targeting a significant unmet need, as a large proportion of STEMI patients do not receive timely antiplatelet therapy per guidelines, leading to worse outcomes.
View full company profile